Want to see IN:MOREPENLAB full AI Analyst Report?
Top Page
Morepen Laboratories Limited
(MOREPENLAB)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹144.00
▲(242.94% Upside)
Action:Reiterated
Date:09/17/26
The score is held back primarily by weak cash-flow quality (persistently negative free cash flow) and some recent margin softening, despite a generally improving earnings profile and a still-manageable balance sheet. Technicals are a notable positive with a strong multi-timeframe uptrend and supportive momentum. Valuation is a secondary headwind due to the high P/E and low dividend yield.
Positive Factors
Multi-year revenue growth
Meaningful revenue growth across several years indicates that Morepen has expanded its commercial base and maintained demand for its pharmaceutical offerings. This supports scale benefits, broader market reach, and a stronger platform for sustaining earnings over the next several quarters.
Negative Factors
Persistent negative free cash flow
Persistent negative free cash flow indicates that accounting earnings are not converting into surplus cash, creating an ongoing cash-burn concern. If this continues, Morepen may have less internally generated funding for investment and greater reliance on financing to support growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue growth
Meaningful revenue growth across several years indicates that Morepen has expanded its commercial base and maintained demand for its pharmaceutical offerings. This supports scale benefits, broader market reach, and a stronger platform for sustaining earnings over the next several quarters.
Read all positive factors
Morepen Laboratories Limited (MOREPENLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹71.10B
Dividend Yield0.15%
Average Volume (3M)1.28M
Price to Earnings (P/E)50.6
Beta (1Y)1.79
Revenue Growth9.48%
EPS Growth50.50%
CountryIN
Employees2,152
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.56
Shares Outstanding547,953,700
10 Day Avg. Volume1,281,394
30 Day Avg. Volume1,283,106
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)1.64
Price to Sales (P/S)1.13
P/FCF Ratio-14.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Morepen Laboratories Limited Business Overview & Revenue Model
Company Description
Morepen Laboratories Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), proprietary and generic pharmaceutical formulations, and...
How the Company Makes Money
Morepen Laboratories makes money primarily by selling (1) active pharmaceutical ingredients (APIs) and intermediates to other pharmaceutical manufacturers and (2) finished dosage formulations (branded generics and other formulations) through domes...
Morepen Laboratories Limited Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
68
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.51B | 18.06B | 18.30B | 17.02B | 14.18B | 15.42B |
| Gross Profit | 6.87B | 6.82B | 6.30B | 6.18B | 2.19B | 4.81B |
| EBITDA | 2.27B | 1.73B | 1.92B | 1.73B | 856.66M | 1.57B |
| Net Income | 1.41B | 948.77M | 1.18B | 961.60M | 386.75M | 1.02B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 19.36B | 17.78B | 12.93B | 11.10B | 10.70B |
| Cash, Cash Equivalents and Short-Term Investments | 916.99M | 916.99M | 1.27B | 169.45M | 216.66M | 158.03M |
| Total Debt | 0.00 | 2.08B | 1.05B | 289.99M | 251.64M | 1.33B |
| Total Liabilities | -12.47B | 6.89B | 5.91B | 4.46B | 3.58B | 4.92B |
| Stockholders Equity | 12.47B | 12.46B | 11.56B | 8.47B | 7.53B | 5.79B |
Cash Flow | ||||||
| Free Cash Flow | -247.12M | -1.44B | -919.76M | -79.61M | -1.37B | -1.25B |
| Operating Cash Flow | 158.61M | 162.28M | 320.57M | 733.75M | -911.71M | -577.58M |
| Investing Cash Flow | -516.43M | -1.22B | -3.22B | -833.00M | -465.09M | -316.79M |
| Financing Cash Flow | 444.06M | 1.13B | 3.00B | 52.05M | 1.44B | 663.34M |
Morepen Laboratories Limited Technical Analysis
Positive
41.99
Price Trends
104.13
Positive
78.23
Positive
59.02
Positive
Market Momentum
9.37
Negative
57.67
Neutral
61.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MOREPENLAB, the sentiment is Positive. The current price of 41.99 is below the 20-day moving average (MA) of 124.23, below the 50-day MA of 104.13, and below the 200-day MA of 59.02, indicating a bullish trend. The MACD of 9.37 indicates Negative momentum. The RSI at 57.67 is Neutral, neither overbought nor oversold. The STOCH value of 61.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MOREPENLAB.
Morepen Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹25.52B | 7.95 | ― | 2.42% | 8.21% | 1.31% | |
70 Outperform | ₹19.56B | 29.91 | ― | 0.66% | 18.53% | 1.89% | |
61 Neutral | ₹71.10B | 50.61 | ― | 0.15% | 9.48% | 50.50% | |
56 Neutral | ₹26.32B | -77.98 | ― | 0.28% | -5.37% | -153.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹31.02B | -1,150.63 | ― | 0.45% | 15.49% | -112.78% | |
47 Neutral | ₹21.37B | 795.52 | ― | 0.09% | 12.08% | ― |
* General Sector Average
IN:MOREPENLAB
Morepen Laboratories Limited
129.75
80.92
165.73%
IN:ALEMBICLTD
Alembic Limited
99.40
3.81
3.99%
IN:HIKAL
Hikal Limited
213.45
-25.87
-10.81%
IN:INDOCO
Indoco Remedies Limited
231.55
-64.04
-21.67%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
645.30
49.95
8.39%
IN:WINDLAS
Windlas Biotech Ltd.
947.95
44.18
4.89%
Morepen Laboratories Limited Corporate Events
Morepen Files First U.S. ANDA to Bolster Integrated CDMO Platform
Sep 28, 2026
Morepen Laboratories has filed its first Abbreviated New Drug Application with the U.S. Food and Drug Administration for Sitagliptin Tablets USP in three strengths, marking its entry into U.S.-bound finished dosage submissions. The move extends it...
Morepen Laboratories posts e‑voting results for 41st AGM
Sep 26, 2026
Morepen Laboratories Limited has reported the e‑voting results for its 41st Annual General Meeting held on September 26, 2026 via video conferencing and other audio‑visual means. The company provided remote and AGM e‑voting facil...
Morepen Laboratories Publishes AGM and Dividend Notice for Investors
Aug 26, 2026
Morepen Laboratories Limited has informed the stock exchanges that it published newspaper notices regarding its 41st Annual General Meeting, dividend declaration and the associated record date. The disclosures appeared in the Financial Express and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.